estim pt
reduc project lower pt
new ep note yet
reflect dis-synergi associ plan exit rx
gener management yet provid estim
growth prospect unclear reduc pt lack clariti
growth prospect three busi segment look forward new
ceo murray kessler growth initi spend plan lower
compound-annual-growth-rate revenue ebita cut pt
old ep new ep target price-to-earnings
discount mean premium vs gener group mean
ep due durabl franchis lower leverag risk
lower estim due reduc rx gener sale plu lower margin
associ reinvest requir lower estim
mainli due increas concern around margin contract lower
gandrogel sale cut revenu estim
guidanc
also lower ep project
manag rang
compound-annual-growth-rate stand
revenu ep ms vs consensu estim
three key earn swing factor dis-synergi associ
plan rx busi exit impact futur earn current
imposs estim time launch gener proair impact rx
segment result current model launch juli invest spend
could increas new ceo kessler intent develop new growth
driver invest better suppli chain manag
duplic api suppli certain rx product
publish novemb indic prepar cost
rx separ rang spend exclud
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
non-gaap figur independ potenti dis-synergi accord
file connect propos separ anticip incur
signific prepar cost exclud restructur expens transact
cost rang million million depend final
structur transact spin-off result cost higher end
rang manag continu target complet rx separ
importantli still await quantif dis-synergi
revenu margin pipelin prospect
project flattish revenu
earn growth come year
organ compound-annual-growth-rate revenu
given new ceo board initi
price target base ep target
price-to-earnings discount mean premium vs gener
specialti pharma group mean ep due busi mix less
pipelin drive earn upsid multipl expans new launch drive
ep expect multipl increas consum segment perform
better expect margin profil improv tuck-in deal add new growth
deliv result line expect growth prospect
remain cloudi manag execut well improv chci
segment perform return modest growth rel
new launch disappoint pressur worsen us consum rx declin
new launch delay competit pressur worsen margin profil
north american store-brand
counter medicin adj op incom
intern consum over-the-counter adj
op incom franchis omega
manag work turn around
prescript rx gener adj op
incom leader gener topic limit
competit gener nich high
quarterli result guidanc updat
gproair launch
risk achiev price
new product launch delay
new invest spend enhanc
prospect higher anticip
dilut associ rx exit wors
expect
exhibit us spec brand gx comp sheet
us specialti brand gener
price
price
spec brand gx mean
spec brand gx median
valuat methodolog risk associ price target rate
recommend referenc research report pleas contact client support
follow us/canada hong kong latin
sydney tokyo altern may contact
invest repres morgan stanley research broadway attent
exhibit incom statement margin analysi valuat
sg sale
 sale
exhibit balanc sheet
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
